Indian pharma majors are facing their toughest year yet in the US, with regulatory clampdown, hostile political environment and falling prices. Is reinvention the answer to their woes?
Generic Indian pharma players are changing their formula to focus on high-margin complex generics and specialty drugs
Outstanding companies that exemplify the power of Indian enterprise
What makes Intas the most valuable privately-held pharma company in India